TPCN2 and rectal cancer: Carriage of TPCN2 rs35264875:TT or rs72932540:GA was associated with a higher risk of developing malignant neoplasm of the rectum (OR: 1.37, 95% CI: 1.02–1.84, P = 0.034*, OR: 1.15, 95% CI: 1.004–1.32, P = 0.044*, respectively, vs. A/A).